Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986205 + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BMS-986205 + nivolumab is an investigational combination therapy consisting of **BMS-986205**, a potent and selective oral inhibitor of **indoleamine 2,3-dioxygenase 1 (IDO1)**, and **nivolumab** (Opdivo), a monoclonal antibody targeting the **programmed cell death protein 1 (PD-1)** checkpoint. The rationale for this combination is to synergistically modulate the immune system in cancer: BMS-986205 inhibits the IDO1-mediated immune suppression pathway, which may contribute to resistance to checkpoint inhibitors, while nivolumab blocks the PD-1 pathway to restore T cell activation against tumor cells. The combination has primarily been investigated in advanced cancers, including hepatocellular carcinoma, bladder cancer, and cervical cancer[1][3][5][7]. Clinical trials have demonstrated a manageable safety profile and signals of efficacy in these cancers.
- Brand names
- Opdivo
- Other names
- BMS-986205 plus nivolumabBMS986205 plus nivolumabBMS 986205 plus nivolumabOpdivo plus BMS-986205
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BMS-986205 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986205 + nivolumab.